We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.00 | -0.98% | 203.00 | 202.00 | 203.00 | 208.00 | 200.00 | 202.00 | 259,276 | 16:35:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.32 | 195.09M |
From Apr 2019 to Apr 2024
By Matteo Castia
Oxford BioMedica PLC said Friday that French pharma group Sanofi SA intends to terminate its collaboration and license agreement with Oxford BioMedica in the field of hemophilia gene therapy.
The gene and cell-therapy group said it expects a negligible impact on revenue in the next 24 months due to the termination.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
March 19, 2021 04:08 ET (08:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
